Genomic Vision announced on Thursday that its new FiberSmart software had been successfully tested and validated by teams from AstraZeneca and the Fritz Lipmann Institute in Germany for the analysis of DNA replication.

This artificial intelligence software, which enables automated recognition of DNA structures, was tested as part of work on cellular replication based on molecular combing technology (RCA).

FiberSmart aims to automate the detection and quantification of fluorescent signals on combed DNA molecules, making it possible to analyze and compare hundreds of thousands of signals automatically and rapidly.

In its press release, Genomic refers to an 'intuitive, simple and fluid' handling and use, as well as a 'user-friendly' interface.

On the Paris Bourse, Genomic Vision shares were up 15% following this announcement.

Copyright (c) 2023 CercleFinance.com. All rights reserved.